14. Expression level of miR-125b in glioma patients

Do Thi Chi, Nguyen Thu Thuy, Tran Van Khanh, Le Thi Phuong, Dong Van He, Nguyen Duc Lien, Kieu Dinh Hung

Main Article Content

Abstract

Glioma is malignant tumor originating from the brain parenchyma. Early diagnosis and targeted treatment are still a problem for modern medicine. Many studies have demonstrated that miRNAs are important in the pathogenesis of glioma, in which miR-125b acts as an oncogene with the highest expression level in brain tissue, promising to become an effective biological marker in diagnosis and treatment. This study aimed to evaluate the expression level of miR-125b in plasma of 62 glioma patients and 62 healthy controls. The results showed that the level of expression of miR-125b was significantly lower in the glioma group (0.77 ± 1.318) compared to the control group (1.165 ± 1.404) (p < 0.001) and in the group of patients under 50 years old (0.318 ± 0.312) compared to the group over 50 years old (1.143 ± 1.678) (p = 0.01). Our data suggests the relation between reduced levels of miR-125b expression and glioma and patient age.

Article Details

References

1. Puranik AD, Rangarajan V, Dev ID, et al. Brain FET PET tumor-to-white mater ratio to differentiate recurrence from post-treatment changes in high-grade gliomas. J. Neuroimaging. 2021;31:1211-1218.
2. M Weller, W Wick, K Aldape, et al. Glioma. Natrev dis primers. 2015;1:15017.
3. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classfication of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97-109.
4. David N Louis, Arie Perry, Guido Reifenberger, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2017;401(16):1545-1.
5. Zülch KJ. Brain Tumors. Berlin-Heidelberg-New York: Springer Verlag; 1986. Their biology and pathology.
6. Zheng Z, Qu JQ, Yi HM, et al. MiR-125b regulates proliferation and apoptosis of nasopharyngeal carcinoma by targeting A20/NF-kappaB signaling pathway. Cell Death Dis. 2017;8(6):e2855.
7. Zhao X, He W, Li J, et al. MiRNA-125b inhibits proliferation and migration by targeting SphK1 in bladder cancer. Am J Transl Res. 2015;7(11):2346-54.
8. Sun Y, Liu X, Zhang Q, et al. Oncogenic potential of TSTA3 in breast cancer and its regulation by the tumor suppressors miR-125a-5p and miR-125b. Tumour Biol. 2016;37(4):4963–4972.
9. Le MTN, Xie H, Zhou B, et al. MicroRNA-125b Promotes Neuronal Differentiation in Human Cells by Repressing Multiple Targets. Mol Cell Biol. 2009;29:52905305.
10. Shi L, Zhang J, Pan T, et al. MiR-125b is critical for the suppression of human U251 glioma stem cell proliferation. Brain Res. 2010;1312:120-126.
11. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402-408. doi:10.1006/meth.2001.1262
12. Reddy KB. MicroRNA (miRNA) in cancer. Cancer Cell Int. 2015;15(38). https://doi.org/10.1186/s12935-015-0185-1.
13. Wang Y, Zeng G, Jiang Y. The Emerging Roles of miR-125b in Cancers. Cancer Manag. Res. 2020;12:1079-1088.
14. Hong-Fei Xia, Tian-Zhu He, Chun-Mei Liu, et al. MiR-125b expression affects the proliferation and apoptosis of human glioma cells by targeting Bmf. Cellular Physiology and Biochemistry. 2009;23(4-6):347-358.
15. Lei Shi, Shuguang Zhang, Kun Feng, et al. MicroRNA-125b-2 confers human glioblastoma stem cells resistance to temozolomide through the mitochondrial pathway of apoptosis. Int J Oncol. 2012;40(1):119-129.
16. Li X, Zheng J, Chen L, et al. Predictive and prognostic roles of abnormal expression of tissue miR-125b, miR-221, and miR-222 in glioma. Mol Neurobiol. 2016; 53: 577-583.
17. XiangTai Wei, Duo Chen, Tao Lv, et al. Serum MicroRNA-125b as a Potential Biomarker for Glioma Diagnosis. Mol Neurobiol. 2016;53(1):163-170.
18. Regazzo G, Terrenato I, Spagnuolo M, et al. A restricted signature of serum miRNAs distinguishes glioblastoma from lower grade gliomas. J Exp Clin Cancer Res. 2016;35:124. https://doi.org/10.1186/s13046-016-0393-0.